New combo therapy shows promise for hard-to-treat hodgkin lymphoma

NCT ID NCT07145125

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated Jun 12, 2026 · Updated 25 times

Summary

This study looked at 222 adults with Hodgkin lymphoma that returned or didn't respond to initial treatment. They received a combination of two drugs, brentuximab vedotin and bendamustine. The goal was to see how well the treatment worked and what side effects occurred in real-world settings, with some patients also going on to a stem cell transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CH de la Côte Basque, service Hématologie Clinique

Bayonne, France
CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire

Bordeaux, France
CHU de Caen, service Hématologie Clinique

Caen, France
CHU de Toulouse, service Hématologie Clinique

Toulouse, France
Institut Paoli Calmettes, service Hématologie Clinique

Marseille, France

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY HODGKIN LYMPHOMA